Psychomeasure

What Psychomeasure does

Psychomeasure is a Portuguese healthtech startup founded in 2019 and headquartered at the PCI Creative Science Park in Ílhavo, near Aveiro. The company develops an AI-powered speech biomarker platform, marketed under the TAPR brand and classified as a Class I Software as a Medical Device (SaMD) in Europe with CE Mark approval from INFARMED. The platform analyzes patient speech through proprietary methods including a Non-Semantic Speech Graph, Latent Semantic Analysis, and a Mental Disorganization Index, feeding into a machine learning classifier trained to differentiate healthy speech patterns from those associated with mental pathologies such as schizophrenia.

The product suite comprises a Clinical Assessment Module that generates real-time diagnostic reports, a Remote Monitoring module for continuous patient tracking, and a Digital Therapeutics offering. Psychomeasure is currently leading the DISA-LNT European project under the THCS Partnership (Horizon Europe), spanning 4 countries, 3 research partners, and 100 participants, in collaboration with VerySA on a co-therapy companion app. The company cites peer-reviewed validation in Nature and PLoS ONE and reports 90%+ diagnostic accuracy for schizophrenia and 100% predictive precision for early psychosis detection in at-risk youth.

Psychomeasure operates an enterprise B2B go-to-market targeting healthcare systems, clinicians, and psychiatric care facilities through direct sales, an Early Access program, and clinical partnership channels. Revenue mechanics are not publicly disclosed but are described as subscription- or licensing-based for clinical use of the diagnostic and monitoring platform. The company is privately held with a team of approximately 6-7 members, has not disclosed any commercial funding rounds, and appears to be primarily funded through non-dilutive European and Portuguese grant programs including FCT, EIC, EIT Health, and PRR.

Name

Psychomeasure

Legal name

Psychomeasure

Website

https://psychomeasure.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

Psychomeasure is a Portuguese healthtech startup that builds TAPR, an AI-powered speech biomarker platform classified as a Class I SaMD, providing diagnostic assessment, remote monitoring, and digital therapeutics for schizophrenia care to clinicians and healthcare systems across Europe.

Ownership category

akta.pro rank

Product category

Digital Mental Health Diagnostics

SIC

Services-Prepackaged Software (7372), Services-Health Services (8000)

akta.pro primary industry

Software as a Medical Device (SaMD) – Clinical Decision & Diagnostic Software (HLACANAD)

akta.pro secondary industries

SaMD – Digital Biomarkers & Algorithmic Endpoints (HLACANAF), SaMD – Monitoring, Triage & Risk Stratification Software (HLACANAE), Therapeutic Companion Apps (Drug-Device-Digital Combination) (HLACANAH)

Keywords

• Speech biomarker analysis
• Digital mental health
• Schizophrenia diagnostics
• AI clinical assessment
• Remote patient monitoring

Headquarters

HQ city

Aveiro

HQ country

Portugal

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Digital Diagnostics & Assessment: SaaS platform providing diagnostic assessment services to healthcare systems and clinicians. Revenue likely generated through subscription/licensing model for clinical use of the diagnostic platform.
2. Digital Therapeutics (DTx): Digital therapeutic interventions including the DISA-LNT project providing digital companion apps for schizophrenia treatment, potentially generating revenue through healthcare system partnerships.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Psychomeasure develops TAPR, an AI-powered speech-based biomarker platform that performs objective mental health assessment and remote monitoring for schizophrenia diagnosis. Classified as a Class I Software as a Medical Device (SaMD) in Europe with CE Mark approval, the platform analyzes speech through Non-Semantic Speech Graphs, Latent Semantic Analysis, and proprietary machine learning classifiers to produce diagnostic and prognostic markers for clinicians. The company also runs the DISA-LNT European digital therapeutics project, deploying a companion co-therapy app for schizophrenia patients.

Product overview

Psychomeasure offers a unified schizophrenia care digital platform centered around its core AI-powered product TAPR. The platform integrates multiple modules: Clinical Assessment for real-time diagnostic reports, Remote Monitoring for continuous patient tracking, and Digital Therapeutics for treatment interventions. The company is also developing DISA-LNT, a European co-therapy companion app for schizophrenia patients. All components leverage speech-based biomarkers analyzed through machine learning to deliver objective, data-driven mental health assessments.

Differentiator

Problem solved

Functional benefit

Brands

• TAPR: AI-powered speech-based biomarker technology platform for mental health assessment and monitoring.

Products and services

• TAPR

Quantifiable outcome

• Reduces misdiagnosis rate from 57% to near-zero through objective biomarkers
• +6 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

Partnerships

Five partnerships are on record, tiered core.

• THCS PartnershipcoreStrategic or Co-development Partner · 1 January 2025European Transforming Health and Care Systems Partnership (GA nº101095654) under Horizon Europe. Project involves 4 European countries, 3 research partners, and 100 participants including 90 schizophrenia patients. FCT (Fundação para a Ciência e Tecnologia) is the funding entity.
• PCI - Creative Science ParkcoreStrategic or Co-development PartnerHost organization for company headquarters, providing innovation ecosystem and infrastructure.
• UA - University of AveirocoreStrategic or Co-development PartnerAcademic partner providing research collaboration and talent development.
• CEUcoreStrategic or Co-development PartnerConsortium partner in DISA-LNT European project for schizophrenia care digital therapeutics.
• VerySAcoreStrategic or Co-development PartnerDigital Therapeutics Schizophrenia Companion (DTxSC) app developer for DISA-LNT project. User-centered companion app designed as co-therapy in schizophrenia treatment.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Woebot Health: Woebot Health builds AI-driven digital therapeutics for mental health, including FDA-cleared products for postpartum depression. Comparable as an AI/DTx mental health company pursuing regulated software-as-medical-device pathways.
• Lyssn: Lyssn provides AI analytics for therapy sessions, including speech and language signal analysis to support mental health practitioners. Its technology scope and target buyer (mental health clinicians) directly overlap with Psychomeasure's TAPR.
• Ellipsis Health: Ellipsis Health applies AI to voice and speech patterns to detect depression and anxiety in clinical and population health settings. It is a direct competitor in the speech-biomarker mental health diagnostic category Psychomeasure serves.
• Akili Interactive: Akili Interactive is a digital therapeutics company with FDA-authorized software for cognitive and mental health conditions. Comparable as a regulated DTx/SaMD mental health company pursuing clinical evidence and payer adoption.
• Wysa: Wysa offers an AI chatbot for mental health support with clinical-grade deployment in health systems and employers. Comparable as an AI-driven mental health platform serving healthcare enterprise buyers.
• Kintsugi: Kintsugi builds voice-based biomarker technology for mental health screening and monitoring, closely paralleling Psychomeasure's speech-based schizophrenia diagnostics. Both target objective behavioral biomarkers from voice/speech as a clinical decision tool.
• Limbic: Limbic builds AI-driven digital mental health tools, including automated patient-facing assessments and therapist-support tools used in NHS pathways. Comparable as an AI-native mental health platform integrated into clinical workflows.

Broad incumbents

• Cerebral: Cerebral provides telehealth psychiatry and mental health treatment including medication management and digital care pathways. Comparable as a tech-enabled mental health services company exploring digital assessment tools.
• Otsuka (Digital Therapeutics): Otsuka has developed and commercialized prescription digital therapeutics for mental health (e.g., reSET, reSET-O) via its Otsuka Pharmaceutical Development & Commercialization arm. Relevant as a large incumbent with regulated DTx experience in psychiatry.
• Spring Health: Spring Health is a broad mental health platform combining provider matching, digital tools, and measurement-based care for employers and health plans. Comparable as a B2B enterprise mental health platform buyer of Psychomeasure's category.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/psychomeasure

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Psychomeasure